Identification of selective inhibitors of Plasmodium N-myristoyltransferase by high-throughput screening.
暂无分享,去创建一个
P. Myler | Gonzalo Colmenarejo | C. Chung | A. Kaushansky | B. Staker | Raquel Fernández-Menéndez | Alexandra R. Reers | Félix Calderón | A. Harupa | L. A. de las Heras | S. Palomo | Manuela Berlanga | Beatriz Rodríguez | Elena Fernández Álvaro | Sally Lyons-Abbott | D. Charter | Esperanza Herreros-Avilés | Ivan Caballero Hernandez
[1] Edward W. Tate,et al. Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors , 2019, Cell chemical biology.
[2] S. Norval,et al. A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors , 2018, Journal of medicinal chemistry.
[3] S. Johnston,et al. Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus , 2018, Nature Chemistry.
[4] A. Holder,et al. N-Myristoylation as a Drug Target in Malaria: Exploring the Role of N-Myristoyltransferase Substrates in the Inhibitor Mode of Action. , 2018, ACS infectious diseases.
[5] K. Paaijmans,et al. malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication , 2017, PLoS medicine.
[6] D. Fidock,et al. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic , 2017, Nature Medicine.
[7] J. Burrows,et al. New developments in anti-malarial target candidate and product profiles , 2017, Malaria Journal.
[8] A. Fairlamb,et al. The N-myristoylome of Trypanosoma cruzi , 2016, Scientific Reports.
[9] S. Agnandji,et al. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials. , 2015, Future microbiology.
[10] Edward W. Tate,et al. Global Analysis of Protein N-Myristoylation and Exploration of N-Myristoyltransferase as a Drug Target in the Neglected Human Pathogen Leishmania donovani , 2015, Chemistry & biology.
[11] Edward W. Tate,et al. Structure-Based Design of Potent and Selective LeishmaniaN-Myristoyltransferase Inhibitors , 2014, Journal of medicinal chemistry.
[12] Edward W. Tate,et al. Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP) , 2014, Journal of medicinal chemistry.
[13] Edward W. Tate,et al. Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach. , 2014, Nature chemistry.
[14] B. Genton,et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.
[15] David M. Wilson,et al. A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery , 2013, PloS one.
[16] Pannamas Maneekan,et al. Border Malaria Associated with Multidrug Resistance on Thailand-Myanmar and Thailand-Cambodia Borders: Transmission Dynamic, Vulnerability, and Surveillance , 2013, BioMed research international.
[17] F. Nosten,et al. Malaria Burden and Artemisinin Resistance in the Mobile and Migrant Population on the Thai–Myanmar Border, 1999–2011: An Observational Study , 2013, PLoS medicine.
[18] M. Llinás,et al. A Tetracycline-Repressible Transactivator System to Study Essential Genes in Malaria Parasites , 2012, Cell host & microbe.
[19] A. Holder,et al. Design and synthesis of inhibitors of Plasmodium falciparum N-myristoyltransferase, a promising target for antimalarial drug discovery. , 2012, Journal of medicinal chemistry.
[20] Edward W. Tate,et al. Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs , 2012, PLoS neglected tropical diseases.
[21] Qiang Fang,et al. Malaria in the Greater Mekong Subregion: heterogeneity and complexity. , 2012, Acta tropica.
[22] Emmanuelle Thinon,et al. A fluorescence-based assay for N-myristoyltransferase activity. , 2012, Analytical biochemistry.
[23] Yongyuth Yuthavong,et al. A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.
[24] A. Hill,et al. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. , 2010, Drug discovery today.
[25] James R. Brown,et al. Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.
[26] Andrew R. Leach,et al. An Introduction to Chemoinformatics , 2003 .
[27] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[28] Sebastian Maurer-Stroh,et al. N-terminal N-myristoylation of proteins: refinement of the sequence motif and its taxon-specific differences. , 2002, Journal of molecular biology.
[29] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[30] K Gubernator,et al. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.
[31] Isabel Coma,et al. Statistics and decision making in high-throughput screening. , 2009, Methods in molecular biology.